¡¡¡¡¡¾²Î¿¼ÎÄÏס¿

¡¡¡¡1 Dorrell M, Uusitaloª²Jarvinen H, Aguilar E, et al. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 2007;52(Suppl 1):S3ª²19

¡¡¡¡2 Matsuda S, Gomi F, Oshima Y, et al. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005;46(3):1062ª²1068

¡¡¡¡3 Obata R, Inoue Y, Iriyama A, et al. Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. Br J Ophthalmol 2007;91(1):100ª²104

¡¡¡¡4 Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laserª²treated rat model. Arch Ophthalmol 2001;119(3):399ª²404

¡¡¡¡5 Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90(3):337ª²341

¡¡¡¡6 Ergun E, Maar N, Ansariª²Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular ageª²related macular degeneration. Am J Ophthalmol 2006;142(1):10ª²16

¡¡¡¡7 Arias L, Garciaª²Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: oneª²year results of a randomized study. Ophthalmology 2006;113(12):2243ª²2250

¡¡¡¡8 Augustin AJ, Schmidtª²Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in ageª²related macular degeneration. Am J Ophthalmol 2006;141(4):638ª²645

¡¡¡¡9 Nicolo M, Ghiglione D, Lai S, et al. Occult with no classic choroidal neovascularization secondary to ageª²related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.

¡¡¡¡Retina 2006;26(1):58ª²64

¡¡¡¡10 Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112(4): 593ª²598

¡¡¡¡11 Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136(5): 791ª²796

¡¡¡¡12 Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90(9):1188ª²1196

¡¡¡¡13 Schmidtª²Erfurth U, Michels S, Michels R, et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to ageª²related macular degeneration. Eur J Ophthalmol 2005;15(4):482ª²485

¡¡¡¡14 Slakter JS, Bochow TW, D¬ðAmico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in ageª²related macular degeneration. Ophthalmology 2006;113(1):3ª²13

¡¡¡¡15 Higgins RD, Yan Y, Geng Y, et al. Regression of retinopathy by squalamine in a mouse model. Pediatr Res 2004;56(1):144ª²149

¡¡¡¡16 Sills AK Jr, Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58(13):2784ª²2792

¡¡¡¡17 Higgins RD, Sanders RJ, Yan Y, et al. Squalamine improves retinal neovascularization. Invest Ophthalmol Vis Sci 2000;41(6):1507ª²1512

¡¡¡¡18 Ciulla TA, Criswell MH, Danis RP, et al. Squalamine lactate reduces choroidal neovascularization in a laserª²injury model in the rat. Retina 2003;23(6):808ª²814

¡¡¡¡19 Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular ageª²related macular degeneration. N Engl J Med 2004;351(27):2805ª²2816

¡¡¡¡20 Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized doubleª²masked trial of pegaptanib, an antiª²vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747ª²1757

¡¡¡¡21 D¬ðAmico DJ, Patel M, Adamis AP, et al. Pegaptanib sodium for neovascular ageª²related macular degeneration: twoª²year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113(6):992ª²1001

¡¡¡¡22 Ishida S, Usui T, Yamashiro K, et al. VEGF164ª²mediated inflammation is required for pathological, but not physiological, ischemiaª²induced retinal neovascularization. J Exp Med 2003;198(3):483ª²489

¡¡¡¡23 Ng EW, Adamis AP. Targeting angiogenesis,the underlying disorder in neovascular ageª²relatedmacular degeneration. Can J Ophthalmol 2005;40(3): 352ª²368

ÉÏÒ»Ò³  [1] [2] [3] ÏÂÒ»Ò³